This company has been acquired
Meridian Bioscience Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Meridian Bioscience.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Medical Equipment earnings growth | 12.5% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | n/a |
Recent future growth updates
Recent updates
Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M
Aug 05Meridian Bioscience: High-Probability Merger Arbitrage
Jul 26Meridian Bioscience downgraded at William Blair on $1.53B acquisition
Jul 07Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet
Jun 27
Meridian Bioscience: Correctly Valued
Jun 26Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital
Jun 09Meridian Bioscience: Deceptively Priced
Mar 14Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns
Feb 03These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely
Jul 19If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy
Jul 08Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine
May 10Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation
May 08Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly
Mar 31Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?
Mar 11Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%
Feb 24Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues
Feb 09
Meridian expands production capacity for COVID-19 tests with NIH funding
Feb 03Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?
Jan 27Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2023 | 288 | 35 | N/A | N/A | 2 |
| 9/30/2022 | 333 | 42 | 74 | 82 | N/A |
| 6/30/2022 | 344 | 43 | 88 | 95 | N/A |
| 3/31/2022 | 339 | 62 | 82 | 91 | N/A |
| 12/31/2021 | 313 | 60 | 59 | 77 | N/A |
| 9/30/2021 | 318 | 71 | 49 | 67 | N/A |
| 6/30/2021 | 306 | 71 | 51 | 69 | N/A |
| 3/31/2021 | 327 | 87 | 60 | 74 | N/A |
| 12/31/2020 | 299 | 70 | 63 | 68 | N/A |
| 9/30/2020 | 254 | 46 | 45 | 48 | N/A |
| 6/30/2020 | 240 | 44 | 36 | 39 | N/A |
| 3/31/2020 | 204 | 21 | 28 | 31 | N/A |
| 12/31/2019 | 197 | 19 | 29 | 32 | N/A |
| 9/30/2019 | 201 | 24 | 32 | 36 | N/A |
| 6/30/2019 | 203 | 26 | 36 | 40 | N/A |
| 3/31/2019 | 207 | 27 | 38 | 42 | N/A |
| 12/31/2018 | 213 | 26 | 35 | 39 | N/A |
| 9/30/2018 | 214 | 24 | 31 | 35 | N/A |
| 6/30/2018 | 210 | 24 | 28 | 32 | N/A |
| 3/31/2018 | 209 | 18 | 26 | 30 | N/A |
| 12/31/2017 | 206 | 22 | 29 | 34 | N/A |
| 9/30/2017 | 201 | 22 | 37 | 41 | N/A |
| 6/30/2017 | 198 | 21 | 39 | 44 | N/A |
| 3/31/2017 | 199 | 30 | 39 | 44 | N/A |
| 12/31/2016 | 195 | 30 | 34 | 38 | N/A |
| 9/30/2016 | 196 | 32 | 33 | 37 | N/A |
| 6/30/2016 | 195 | 35 | N/A | 38 | N/A |
| 3/31/2016 | 192 | 36 | N/A | 41 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if VIVO's forecast earnings growth is above the savings rate (2%).
Earnings vs Market: Insufficient data to determine if VIVO's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if VIVO's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if VIVO's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if VIVO's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VIVO's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/02/01 04:09 |
| End of Day Share Price | 2023/01/30 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2022/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Meridian Bioscience, Inc. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Mark Massaro | Canaccord Genuity |
| Zarak Khurshid | Caris & Company |